{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:15:08Z","timestamp":1787685308822,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,2]]},"DOI":"10.7759\/cureus.14797","type":"journal-article","created":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T07:59:11Z","timestamp":1619942351000},"source":"Crossref","is-referenced-by-count":9,"title":["Management of Lassa Fever: A Current Update"],"prefix":"10.7759","author":[{"given":"Ammar","family":"Alli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Fernando","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie P","family":"Fabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrapali","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taras","family":"Halan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2019.08.002","article-title":"Lassa fever diagnostics: past, present, and future","volume":"37","author":"Happi AN","year":"2019","unstructured":"Happi AN, Happi CT, Schoepp RJ. Lassa fever diagnostics: past, present, and future. Curr Opin Virol. 2019, 37:132-8. 10.1016\/j.coviro.2019.08.002","journal-title":"Curr Opin Virol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40696-016-0018-3","article-title":"Lassa fever: another threat from West Africa","volume":"2","author":"Brosh-Nissimov T","year":"2016","unstructured":"Brosh-Nissimov T. Lassa fever: another threat from West Africa. Disaster Mil Med. 2016, 2:8. 10.1186\/s40696-016-0018-3","journal-title":"Disaster Mil Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.08.002","article-title":"Lassa fever: epidemiology, clinical features, diagnosis, management and prevention","volume":"33","author":"Asogun DA","year":"2019","unstructured":"Asogun DA, G\u00fcnther S, Akpede GO, Ihekweazu C, Zumla A. Lassa fever: epidemiology, clinical features, diagnosis, management and prevention. Infect Dis Clin North Am. 2019, 33:933-51. 10.1016\/j.idc.2019.08.002","journal-title":"Infect Dis Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)30780-X","article-title":"Lassa virus infection in Nigeria: clinical perspective overview","volume":"102","author":"Idemyor V","year":"2010","unstructured":"Idemyor V. Lassa virus infection in Nigeria: clinical perspective overview. J Natl Med Assoc. 2010, 102:1243-6. 10.1016\/S0027-9684(15)30780-X","journal-title":"J Natl Med Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick JB","year":"1986","unstructured":"McCormick JB, King IJ, Webb PA, et al.. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986, 314:20-6. 10.1056\/NEJM198601023140104","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(84)90107-x","article-title":"The use of Lassa fever convalescent plasma in Nigeria","volume":"78","author":"Frame JD","year":"1984","unstructured":"Frame JD, Verbrugge GP, Gill RG, Pinneo L. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg. 1984, 78:319-24. 10.1016\/0035-9203(84)90107-x","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3201\/eid2506.181035","article-title":"Epidemiologic and clinical features of Lassa fever outbreak in Nigeria, January 1-May 6, 2018","volume":"25","author":"Ilori EA","year":"2019","unstructured":"Ilori EA, Furuse Y, Ipadeola OB, et al.. Epidemiologic and clinical features of Lassa fever outbreak in Nigeria, January 1-May 6, 2018. Emerg Infect Dis. 2019, 25:1066-74. 10.3201\/eid2506.181035","journal-title":"Emerg Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1086\/374853","article-title":"Imported Lassa fever in Germany: surveillance and management of contact persons","volume":"36","author":"Haas WH","year":"2003","unstructured":"Haas WH, Breuer T, Pfaff G, et al.. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis. 2003, 36:1254-8. 10.1086\/374853","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2013.05.015","article-title":"Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012)","volume":"17","author":"Ajayi NA","year":"2013","unstructured":"Ajayi NA, Nwigwe CG, Azuogu BN, et al.. Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012). Int J Infect Dis. 2013, 17:e1011-6. 10.1016\/j.ijid.2013.05.015","journal-title":"Int J Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002748","article-title":"Lassa fever in post-conflict Sierra Leone","volume":"8","author":"Shaffer JG","year":"2014","unstructured":"Shaffer JG, Grant DS, Schieffelin JS, et al.. Lassa fever in post-conflict Sierra Leone. PLoS Negl Trop Dis. 2014, 8:e2748. 10.1371\/journal.pntd.0002748","journal-title":"PLoS Negl Trop Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2017.304186","article-title":"Mortality among confirmed Lassa fever cases during the 2015-2016 outbreak in Nigeria","volume":"108","author":"Buba MI","year":"2018","unstructured":"Buba MI, Dalhat MM, Nguku PM, et al.. Mortality among confirmed Lassa fever cases during the 2015-2016 outbreak in Nigeria. Am J Public Health. 2018, 108:262-4. 10.2105\/AJPH.2017.304186","journal-title":"Am J Public Health"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s1286-4579(01)01508-8","article-title":"Monitoring of clinical and laboratory data in two cases of imported Lassa fever","volume":"4","author":"Schmitz H","year":"2002","unstructured":"Schmitz H, K\u00f6hler B, Laue T, et al.. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect. 2002, 4:43-50. 10.1016\/s1286-4579(01)01508-8","journal-title":"Microbes Infect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever","volume":"65","author":"Raabe VN","year":"2017","unstructured":"Raabe VN, Kann G, Ribner BS, et al.. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis. 2017, 65:855-9. 10.1093\/cid\/cix406","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.05.006","article-title":"Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus","volume":"91","author":"\u00d6lschl\u00e4ger S","year":"2011","unstructured":"\u00d6lschl\u00e4ger S, Neyts J, G\u00fcnther S. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res. 2011, 91:89-93. 10.1016\/j.antiviral.2011.05.006","journal-title":"Antiviral Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02185-18","article-title":"Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses","volume":"3","author":"Hulseberg CE","year":"2019","unstructured":"Hulseberg CE, F\u00e9n\u00e9ant L, Szyma\u0144ska-de Wijs KM, et al.. Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses. J Virol. 2019, 3:02185-18. 10.1128\/JVI.02185-18","journal-title":"J Virol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104701","article-title":"The antifungal isavuconazole inhibits the entry of Lassa virus by targeting the stable signal peptide-GP2 subunit interface of Lassa virus glycoprotein","volume":"174","author":"Zhang X","year":"2020","unstructured":"Zhang X, Tang K, Guo Y. The antifungal isavuconazole inhibits the entry of Lassa virus by targeting the stable signal peptide-GP2 subunit interface of Lassa virus glycoprotein. Antiviral Res. 2020, 174:104701. 10.1016\/j.antiviral.2019.104701","journal-title":"Antiviral Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(92)90073-e","article-title":"Unexpected adverse reactions during a clinical trial in rural West Africa","volume":"19","author":"Fisher-Hoch SP","year":"1992","unstructured":"Fisher-Hoch SP, Gborie S, Parker L, Huggins J. Unexpected adverse reactions during a clinical trial in rural West Africa. Antiviral Res. 1992, 19:139-147. 10.1016\/0166-3542(92)90073-e","journal-title":"Antiviral Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.11.132","article-title":"Progress in the experimental therapy of severe arenaviral infections","volume":"6","author":"Gowen BB","year":"2011","unstructured":"Gowen BB, Bray M. Progress in the experimental therapy of severe arenaviral infections. Future Microbiol. 2011, 6:1429-41. 10.2217\/fmb.11.132","journal-title":"Future Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1086\/657315","article-title":"Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever","volume":"51","author":"Bausch DG","year":"2010","unstructured":"Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis. 2010, 51:1435-41. 10.1086\/657315","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/095632020101200501","article-title":"Mechanisms of action of ribavirin in antiviral therapies","volume":"12","author":"Tam RC","year":"2001","unstructured":"Tam RC, Lau JY, Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother. 2001, 12:261-72. 10.1177\/095632020101200501","journal-title":"Antivir Chem Chemother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/v4112514","article-title":"Advanced vaccine candidates for Lassa fever","volume":"4","author":"Lukashevich IS","year":"2012","unstructured":"Lukashevich IS. Advanced vaccine candidates for Lassa fever. Viruses. 2012, 4:2514-57. 10.3390\/v4112514","journal-title":"Viruses"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/56658-management-of-lassa-fever-a-current-update","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:05Z","timestamp":1707507005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/56658-management-of-lassa-fever-a-current-update"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,2]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.14797","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,2]]}}}